Insight Molecular Diagnostics (IMDX) Operating Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) operating margin from Mar 31, 2020 to Mar 31, 2026. The current Insight Molecular Diagnostics (IMDX) operating margin is -14700.00%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Operating Margin
Quarterly Operating Margin
Annual Operating Margin change of Insight Molecular Diagnostics (IMDX)
| Year | Operating Margin | Change |
|---|---|---|
| 2025 | -1259.11% | -61.22% |
| 2024 | -3246.81% | +93.72% |
| 2023 | -1676.00% | -10.61% |
| 2022 | -1875.00% | -23.21% |
| 2021 | -2441.82% | +0.27% |
| 2020 | -2435.25% | +118.55% |
| 2020 | -1114.29% | -82.21% |
| 2020 | -6264.29% | -85.14% |
| 2020 | -42150.00% | N/A |
Comparison Insight Molecular Diagnostics (IMDX) operating margin with competitors
Insight Molecular Diagnostics (IMDX) operating margin is -14700.00%.
| Ticker | Name | Operating Margin | Upside |
|---|---|---|---|
| IDXX | Idexx Laboratories Inc | 31.78% | -100.22% |
| SHC | Sotera Health Company | 28.16% | -100.19% |
| MTD | Mettler-Toledo International Inc | 26.00% | -100.18% |
| DHR | Danaher Corp | 22.58% | -100.15% |
| QGEN | Qiagen NV | 22.29% | -100.15% |
| A | Agilent Technologies Inc | 21.74% | -100.15% |
| MEDP | Medpace Holdings Inc | 20.03% | -100.14% |
| TMO | Thermo Fisher Scientific Inc | 16.93% | -100.12% |
| BLLN | Billiontoone Inc - Class A | 16.45% | -100.11% |
| VCYT | Veracyte Inc | 16.28% | -100.11% |
| DGX | Quest Diagnostics Inc | 13.78% | -100.09% |
| IQV | IQVIA Holdings Inc | 12.38% | -100.08% |
| CRL | Charles River Laboratories International Inc | 12.04% | -100.08% |
| LH | Laboratory Corp Of America Holdings | 10.76% | -100.07% |
| RVTY | Revvity Inc | 10.67% | -100.07% |
| ICLR | Icon Plc | 5.37% | -100.04% |
| CDNA | Caredx Inc | 1.02% | -100.01% |